ЗА ПО-ДОБРО БЪДЕЩЕ
Големите открития се дължат на страстта, ангажираността и отдадеността на хора, екипи и компании, които работят за откриването и разработването на нови лекарства за пациентите.
Прочетете посланията, на експертите които не спират да работят, за да стане светът по-здравословно място.
Иновацията във фармацията има смисъл само, когато достига до нуждаещите се от нея. Ние #НямаДаСпрем докато достиженията на науката не станат достъпни за българските пациенти.
Генерален мениджър, Абви ЕООД
Кирил Николчев, България
През следващите години фармацевтичната индустрия ще разработи нови терапии за нерешените проблеми в онкологията, диабета, хемофилията, болест на Алцхаймер, инфекциите, чернодробни заболявания, мигрената. Ние #НямаДаСпрем, докато не осигурим шанс на всеки български пациент да се лекува с най-добрите терапии.
Изпълнителен директор, ARPharM
Деян Денев, България
We Won’t Rest until our innovative medicines are made available to all eligible cancer patients worldwide.
President, Europe & Canada, Takeda
Giles Platford, Zurich, Switzerland
#WeWontRest until we have found a cure for Type 1 Diabetes.
Head of Europe Diabetes & Cardiovascualr Business Units, Sanofi
Marc-Antoine Lucchini, France
Director Medical Affairs Infectious Diseases, MSD.
Brand Manager, AbbVie
Karin Hagen, Sweden
#WeWontRest until we develop transformational vaccines to prevent, intercept, treat and cure life-threatening infectious diseases.
Global Head, Janssen Vaccines, Janssen
Johan Van Hoof, The Netherlands
#WeWontRest until every cancer patient can return to a normal life.
Managing Director Italy, MSD
Nicoletta Luppi, Italy
As precision medicine opens new doors in the treatment of cancer, we must overcome challenges in finding the right patient for the right treatment. #WeWontRest until patients can be considered for multiple trials on the basis of a single molecular screening.
Head of External Innovation, Merck
Dr. Joern-Peter Halle, Germany
We won't rest in research to develop new drugs that can cure diseases that still do not have effective solutions.
Head of Clinical Research, Grupo Menarini España
Isabel Paredes, Spain
#WeWontRest until hepatitis C is eliminated
Brand Manager, AbbVie
Victoria Black, UK
#WeWontRest until we live in a world in which no one suffers or dies from a vaccine-preventable disease.
General Manager, Sanofi UK, Sanofi
Hugo Fry, UK
#WeWontRest. Migraine matters and we are committed to working with the migraine community to discover new ways to improve people’s lives and give patients the voice they deserve.
Worldwide Head Neuroscience, Novartis
#WeWontRest until we unlock data sets all over Europe that will drive research and shape more effective patient care.
Director General, EFPIA
Nathalie Moll, Belgium
I won’t rest until patients can use their smartphones to give us trial feedback in real time.
R&D Operations Innovation Director, Janssen
#WeWontRest until we have the best teams working together to find new innovative therapies that help patients live longer and healthier lives.
Head of Commercial and Innovation, Roche Region Europe
#WeWontRest until we include patient insights in the planning of every clinical program.
Global Head Patient Affairs and Policy, Chief Medical Office, Novartis
#WeWontRest to support and conduct clinical trials until diseases have lost their negative impact on human lives.
President (Pharmig)/ CEO (Amgen Austria), Pharmig/Amgen Austria
Martin Munte, Austria
We have advanced science and medicine to provide a cure for Hepatitis C and #WeWontRest until we have eliminated it.
Hepatitis C Brand Team Leader, AbbVie
Nuria de Diego , Spain
#WeWontRest until not one person loses their life to a vaccine-preventable illness.
Vice President Commercial Development, International Developed Markets, Pfizer
Pascale Mauran, France
#WeWontRest until we bring new advances and pioneering therapies in migraine to the patients that need them the most worldwide.
Global Head, Neuroscience Development, Novartis
#WeWontRest until health is embedded in all policies, to achieve healthier lives at all ages and stages, wherever we live.
Director General, IFPMA
Thomas B. Cueni, Switzerland
#WeWontRest until we have helped asthma patients to #LiveEveryBreath.
Respiratory Global Franchise Medical Head, GSK
#WeWontRest while opportunities exist to leverage innovative technologies to ensure the safety and wellbeing of our patients.
Pharmacovigilance Innovation Senior Specialist, Global Drug Safety & Risk Management, Celgene
#WeWontRest in our objective to transform the way cancer is treated allowing patients to achieve better health results and better quality of life.
Oncology Head of Medical Affairs, AbbVie
Gema García Ledo, Spain
#WeWontRest in our Research efforts to bring innovative medicines that makes a real difference to all patients’ lives.
Senior Executive Vice-President Research and Development, Servier
#WeWontRest until we incorporate the patient voice in the treatment decision making process and ensure patients as key stakeholders.
Patient Experience Solution Lead, Immunology Patient Value Unit, UCB
Virginia Zumárraga, Spain
#WeWontRest until diagnosis becomes easier for every disease.
Value and Access Lead, Sanofi Genzyme
Walter Mei, Italy
#WeWontRest until we have helped eradicate all vaccine-preventable diseases.
SVP – Head of Research & Development, GSK Vaccines
The World Health Organisation (WHO) places migraine as the top 10 of the most disabling diseases. #WeWontRest until migraine becomes a manageable condition.
Senior Director, Pain Discovery UK, Lilly
Lisa Broad, UK
#WeWontRest to ensure that our medicines, clinical trials and services meet the expectations of patients and patient organisations.
Member of the Board of Managing Directors, Boehringer Ingelheim
Allan Hillgrove, Germany
#WeWontRest until insights from individual patient experiences of living with and managing disease are built into every part of the lifecycle of our medicines and vaccines.
Group President, Innovative Health, Pfizer
#WeWontRest in our endeavor to find innovative solutions that make a difference in the lives of patients affected by serious medical conditions
Head of Research & Development, Bayer
Jörg Möller, Germany
#WeWontRest until all of the outstanding unmet need across the spectrum of SMA disease is addressed and the full impact of treatment is fully understood.
Head of Marketing SMA, Europe & Canada, Biogen
Tracy-Jane Bailey-Burnley, Switzerland
#WeWontRest until we make it possible for every eligible patient to participate in a clinical trial – irrespective their location, socio-economic status, age, mobility - and we make this participation an all-round positive experience for them.
Global Head for Trial Operations, Sanofi
Terttu Haring, The Netherlands/France
Alzheimer’s: forgetting what was so obvious before. We continue to strive to find a treatment that modifies the course of the disease and #WeWontRest until we do so.
Country Manager Belgium/Luxembourg, Lilly
Frederic Clais, Belgium